The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.

Heidelberg Engineering GmbH recently launched two new products, OCT2, the next generation OCT module for Spectralis diagnostic imaging, and the Heyex picture archiving and communication system (PACS).

There is no question that certain vision care plans have dominated the eyecare market for the last two decades. Nearly 100 million Americans are covered by just two of these plans. As they have become dominant and integrated into new lines of business, they increasingly are coercing optometrists, ophthalmologists, independent laboratories, and consumers-the result higher, prices less choice, and reduced competition.

Genetic testing in AMD is a relatively new focus for optometrists and an important one to ensure that we are getting a complete view of our patients’ risk for developing advanced AMD. Although we are making some progress, we still have work to do to gain a better understanding of how to incorporate its use into clinical practice.

A recent report from business research firm IBISWorld ranked optometry as one of the top industries for women. The firm analyzed data from the Bureau of Labor Statistics and a database of more than 700 industry reports to identify six industries that offer unique employment advantages for women, characterized by strong growth in revenue and employment, particularly in the number of female workers.

TearLab recently announced that preliminary results of the TearLab Cataract Study, which evaluated the relationship of a hyperosmolar tear film on keratometry readings.

The Brien Holden Institute recently announced it had developed a software program that can automatically assess damage to epithelial cells at the upper eyelid margin.

Novaliq GmbH recently reported positive Phase 1 results with its cyclosporin solution eye drop formulation in clinical development for patients with dry eye.

The International Classification of Diseases, 10th Edition (ICD-10) code is scheduled for implementation in the U.S. on Oct. 1, 2015-less than a year from now. Many optometric practices will likely be unprepared and therefore at risk for serious claim-filing and cash flow problems, according to Rebecca Wartman, OD, the American Optometric Association's (AOA) point person on ICD-10.

Most of us would probably say that the vast majority of our patients are quite satisfied with the care they receive in our offices. But how do we know this for sure?

The U.S. Food and Drug Administration (FDA) recently approved Eylea (afilbercept, Regeneron) for all forms of macular edema after retinal vein occlusion, including branch retinal vein occlusion.

California’s Medicaid program, Medi-Cal, will begin to cover teledenistry services on Jan. 1, 2015, making it one of the first states to do so.

Bono, the iconic Irish rocker and front man for band U2, recently revealed on The Graham Norton Show that he does not wear his avant-garde designer shades for fashion alone.

In his second installment for his Optometry Times blog, The Schachter Factor, Dr. Scott Schachter discusses his protocol for diagnosing and treating dry eye patients in his practice.

A recent survey from Technology Advice found that 25 percent of adults are using a fitness tracker or smartphone app to track their health, weight, or exercise. But according to a report from Venture Beat, physicians are hesitant of the data produced by fitness trackers.

A study published in The British Journal of Ophthalmology found that corneal collagen crosslinking appears to be an effective procedure in the management of superficial microbial keratitis.

After epidemiological studies on the association between vitamin C intake and lung cancer risk produced inconsistent results, researchers conducted a meta-analysis of 21 studies to assess the association.

Ohr Pharmaceutical recently announced details of the planned Phase III registration trials for squalamine eye drops (OHR-102) in the treatment of wet age-related macular degeneration (AMD), which are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent "end of Phase II" meeting.

It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!

Where is the research and development in care systems for these patients? Where is the development of new gas permeable materials?